Medidata announced that ONO PHARMACEUTICAL CO., LTD has expanded its adoption of the Medidata Clinical Cloud® to include all clinical trials testing the use of OPDIVO® (nivolumab) against a broad range of cancers. The company will leverage Medidata's electronic data capture and management technology (Medidata Rave®) to evaluate additional indications for OPDIVO, a cutting-edge immunotherapy drug that was initially approved to treat metastatic melanoma.